unitedhealthcare semaglutide UnitedHealth Group execs eye more affordable GLP-1s semaglutide kaiser permanente Wegovy coverage

44 The 52-week data from 966 patients with MASH and F1B, F2, or F3 fibrosis in the MAESTRO-NASH trial revealed significant effects of resmetirom on MASH resolution, fibrosis improvement, and LDL cholesterol reduction (NCT03900429), 77 forming the basis for potential FDA approval of resmetirom for MASH treatment

High surfactant load, crystallizing actives, incompatible fragrance, corrosion particles or dried residue near the nozzle can restrict flow

They can often be managed by changing cleaning solutions or switching to a preservative-free formulation

The confirmatory secondary endpoint was the change in body weight from baseline to week 30